Key facts
- This page summarizes Jason Ehrlich's Form 4 filing for Kodiak Sciences Inc. (KOD).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Jul 2021, 16:37.
Jason Ehrlich - 20 Jul 2021 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)
- Reporting relationship
- Chief Medical Officer and Chief Development Officer
- Issuer ticker
- KOD
- Reported as of
- 20 Jul 2021
- Net transaction value
- -$599,624
- SEC form
- 4
- Accepted by SEC
- 22 Jul 2021, 16:37:28 UTC
- Prior SEC filing
- 23 Jun 2021
- Next SEC filing
- 13 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Ehrlich filed Form 4 for Kodiak Sciences Inc. (KOD) on 22 Jul 2021.
Change
- Previous filing in this sequence was filed on 23 Jun 2021.
- Current net transaction value: -$599,624.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KOD
transaction
Common Stock
Sale
- Transaction value
- $191,589
- Shares
- -2,234
- Change %
- -3.7%
- Price
- $85.76*
- Shares after
- 57,949
- Date
- 20 Jul 2021
- Ownership
- Direct
- Footnotes
- F1, F2
KOD
transaction
Common Stock
Sale
- Transaction value
- $408,035
- Shares
- -4,716
- Change %
- -8.1%
- Price
- $86.52*
- Shares after
- 53,233
- Date
- 20 Jul 2021
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
Footnote F2
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $85.085 to $86.085, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
Footnote F3
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $86.09 to $86.89, inclusive.
SEC remarks
Chief Medical Officer and Chief Development Officer